News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InViragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore


6/16/2011 8:46:43 AM

SINGAPORE--(BUSINESS WIRE)--Inviragen announced today the initiation of the first clinical trial of the Company’s proprietary Hand, Foot and Mouth Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71 (EV71). The study will be conducted in Singapore at the Investigational Medicine Unit at the National University Health System under Inviragen’s memorandum of understanding with the Duke-NUS Graduate Medical School. This Phase 1 clinical trial of INV21 will assess the safety of the vaccine as well as immune responses in healthy adult volunteers.

Read at BioSpace.com


comments powered by Disqus
InViragen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES